Acute intestinal infections: Current and upcoming vaccines;Infections intestinales aiguës : Vaccins actuels et futurs

Presse Medicale

Volumn 42, Issue 1, 2013, Pages 93-101

  Erlich, Paul ^a   Sansonetti, Philippe J ^a,b  

^a INSTITUT PASTEUR   (France)

^b Centre de Recherche Interdisciplinaire en Biologie   (France)

Author keywords

[No Author keywords available]

Indexed keywords

VACCINE;

DRUG COST; DRUG EFFICACY; HUMAN; IMMUNE RESPONSE; IMMUNE STATUS; INFECTION PREVENTION; INTESTINE INFECTION; SHORT SURVEY; TRAVEL; VACCINATION;

ACUTE DISEASE; BACTERIAL INFECTIONS; GASTROENTEROLOGY; HUMANS; INFECTION; INTESTINAL DISEASES; INTESTINAL DISEASES, PARASITIC; VACCINES; VIRUS DISEASES;

EID: 84872005981     PISSN: 07554982     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lpm.2012.10.011     Document Type: Short Survey

References (39)

1. Fischer Walker C.L., Aryee M.J., Boschi-Pinto C., Black R.E. Estimating diarrhea mortality among young children in low and middle income countries. PloS one 2012, 7:e29151.
2. Boschi-Pinto C., Velebit L., Shibuya K. Estimating child mortality due to diarrhoea in developing countries. Bull World Health Organization 2008, 86:710-717.
3. Steele D., Riddle M., van de Verg L., Bourgeois L. Vaccines for enteric diseases: a meeting summary. Exp Rev Vacc 2012, 11:407-409.
4. Clemens J.D., Sack D.A., Harris J.R., Van Loon F., Chakraborty J., Ahmed F., et al. Field trial of oral cholera vaccines in Bangladesh: results from three-year follow-up. Lancet 1990, 335:270-273.
5. Lucas M.E., Deen J.L., von Seidlein L., Wang X.Y., Ampuero J., Puri M., et al. Effectiveness of mass oral cholera vaccination in Beira, Mozambique. New Engl J Med 2005, 352:757-767.
6. Taylor D.N., Cardenas V., Sanchez J.L., Begue R.E., Gilman R., Bautista C., et al. Two-year study of the protective efficacy of the oral whole cell plus recombinant B subunit cholera vaccine in Peru. J Infect Dis 2000, 181:1667-1673.
7. Chowdhury M.I., Sheikh A., Qadri F. Development of Peru-15 (CholeraGarde), a live-attenuated oral cholera vaccine: 1991-2009. Exp Rev Vacc 2009, 8:1643-1652.
8. Cohen M.B., Giannella R.A., Bean J., Taylor D.N., Parker S., Hoeper A., et al. Randomized, controlled human challenge study of the safety, immunogenicity, and protective efficacy of a single dose of Peru-15, a live attenuated oral cholera vaccine. Infect Immun 2002, 70:1965-1970.
9. Qadri F., Chowdhury M.I., Faruque S.M., Salam M.A., Ahmed T., Begum Y.A., et al. Peru-15, a live attenuated oral cholera vaccine, is safe and immunogenic in Bangladeshi toddlers and infants. Vaccine 2007, 25:231-238.
10. Fraser A., Paul M., Goldberg E., Acosta C.J., Leibovici L. Typhoid fever vaccines: systematic review and meta-analysis of randomised controlled trials. Vaccine 2007, 25:7848-7857.
11. Levine M.M., Ferreccio C., Abrego P., Martin O.S., Ortiz E., Cryz S. Duration of efficacy of Ty21a, attenuated Salmonella typhi live oral vaccine. Vaccine 1999, 17(Suppl. 2):S22-S27.
12. Mai N.L., Phan V.B., Vo A.H., Tran C.T., Lin F.Y., Bryla D.A., et al. Persistent efficacy of Vi conjugate vaccine against typhoid fever in young children. New Engl J Med 2003, 349:1390-1391.
13. Lin F.Y., Ho V.A., Khiem H.B., Trach D.D., Bay P.V., Thanh T.C., et al. The efficacy of a Salmonella typhi Vi conjugate vaccine in two-to-five-year-old children. New Engl J Med 2001, 344:1263-1269.
14. Tacket C.O., Levine M.M. CVD 908, CVD 908-htrA, and CVD 909 live oral typhoid vaccines: a logical progression. Clinical infectious diseases. Infect Dis Soc Am 2007, 45(Suppl. 1):S20-S23.
15. Peltola H., Siitonen A., Kyronseppa H., Simula I., Mattila L., Oksanen P., et al. Prevention of travellers' diarrhoea by oral B-subunit/whole-cell cholera vaccine. Lancet 1991, 338:1285-1289.
16. Svennerholm A.M., Lundgren A. Recent progress toward an enterotoxigenic Escherichia coli vaccine. Exp Rev Vacc 2012, 11:495-507.
17. Rahman K.M., Arifeen S.E., Zaman K., Rahman M., Raqib R., Yunus M., et al. Safety, dose, immunogenicity, and transmissibility of an oral live attenuated Shigella flexneri 2a vaccine candidate (SC602) among healthy adults and school children in Matlab, Bangladesh. Vaccine 2011, 29:1347-1354.
18. Barnoy S., Baqar S., Kaminski R.W., Collins T., Nemelka K., Hale T.L., et al. Shigella sonnei vaccine candidates WRSs2 and WRSs3 are as immunogenic as WRSS1, a clinically tested vaccine candidate, in a primate model of infection. Vaccine 2011, 29:6371-6378.
19. Simon J.K., Maciel M., Weld E.D., Wahid R., Pasetti M.F., Picking W.L., et al. Antigen-specific IgA B memory cell responses to Shigella antigens elicited in volunteers immunized with live attenuated Shigella flexneri 2a oral vaccine candidates. Clin Immunol 2011, 139:185-192.
20. McKenzie R., Walker R.I., Nabors G.S., Van De Verg L.L., Carpenter C., Gomes G., et al. Safety and immunogenicity of an oral, inactivated, whole-cell vaccine for Shigella sonnei: preclinical studies and a Phase I trial. Vaccine 2006, 24:3735-3745.
21. Riddle M.S., Kaminski R.W., Williams C., Porter C., Baqar S., Kordis A., et al. Safety and immunogenicity of an intranasal Shigella flexneri 2a Invaplex 50 vaccine. Vaccine 2011, 29:7009-7019.
22. Phalipon A., Tanguy M., Grandjean C., Guerreiro C., Belot F., Cohen D., et al. A synthetic carbohydrate-protein conjugate vaccine candidate against Shigella flexneri 2a infection. J Immunol 2009, 182:2241-2247.
23. Nielsen L.N., Luijkx T.A., Vegge C.S., Johnsen C.K., Nuijten P., Wren B.W., et al. Identification of immunogenic and virulence-associated Campylobacter jejuni proteins. Clin Vacc Immunol: CVI 2012, 19:113-119.
24. Tribble D.R., Baqar S., Scott D.A., Oplinger M.L., Trespalacios F., Rollins D., et al. Assessment of the duration of protection in Campylobacter jejuni experimental infection in humans. Infection Immun 2010, 78:1750-1759.
25. Jagusztyn-Krynicka E.K., Laniewski P., Wyszynska A. Update on Campylobacter jejuni vaccine development for preventing human campylobacteriosis. Exp Rev Vacc 2009, 8:625-645.
26. O'Ryan M., Lucero Y., Linhares A.C. Rotarix(R): vaccine performance 6 years postlicensure. Exp Rev Vacc 2011, 10:1645-1659.
27. Block S.L., Vesikari T., Goveia M.G., Rivers S.B., Adeyi B.A., Dallas M.J., et al. Efficacy, immunogenicity, and safety of a pentavalent human-bovine (WC3) reassortant rotavirus vaccine at the end of shelf life. Pediatrics 2007, 119:11-18.
28. Glass R.I., Bhan M.K., Ray P., Bahl R., Parashar U.D., Greenberg H., et al. Development of candidate rotavirus vaccines derived from neonatal strains in India. J Infect Dis 2005, 192(Suppl. 1):S30-S35.
29. Barnes G.L., Lund J.S., Adams L., Mora A., Mitchell S.V., Caples A., et al. Phase 1 trial of a candidate rotavirus vaccine (RV3) derived from a human neonate. J Paediatr Child Health 1997, 33:300-304.
30. Bhandari N., Sharma P., Taneja S., Kumar T., Rongsen-Chandola T., Appaiahgari M.B., et al. A dose-escalation safety and immunogenicity study of live attenuated oral rotavirus vaccine 116E in infants: a randomized, double-blind, placebo-controlled trial. J Infect Dis 2009, 200:421-429.
31. Herbst-Kralovetz M., Mason H.S., Chen Q. Norwalk virus-like particles as vaccines. Exp Rev Vacc 2010, 9:299-307.
32. Atmar R.L., Bernstein D.I., Harro C.D., Al-Ibrahim M.S., Chen W.H., Ferreira J., et al. Norovirus vaccine against experimental human Norwalk virus illness. New Engl J Med 2011, 365:2178-2187.
33. Mead J.R. Challenges and prospects for a Cryptosporidium vaccine. Future Microbiol 2010, 5:335-337.
34. Abd Alla M.D., Wolf R., White G.L., Kosanke S.D., Cary D., Verweij J.J., et al. Efficacy of a Gal-lectin subunit vaccine against experimental Entamoeba histolytica infection and colitis in baboons (Papio sp.). Vaccine 2012, 30:3068-3075.
35. Simon J., Kotloff K. New and candidate vaccines for gastrointestinal infections. Curr Opin Gastroenterol 2010, 26:12-16.
36. Serazin A.C., Shackelton L.A., Wilson C., Bhan M.K. Improving the performance of enteric vaccines in the developing world. Nature Immunol 2010, 11:769-773.
37. Pasetti M.F., Simon J.K., Sztein M.B., Levine M.M. Immunology of gut mucosal vaccines. Immunoll Rev 2011, 239:125-148.
38. Garcia L., Jidy M.D., Garcia H., Rodriguez B.L., Fernandez R., Ano G., et al. The vaccine candidate Vibrio cholerae 638 is protective against cholera in healthy volunteers. Infect Immun 2005, 73:3018-3024.
39. Chen S.C., Tan L.B., Huang L.M., Chen K.T. Rotavirus infection and the current status of rotavirus vaccines. J Formosan Med Assoc=Taiwan yi zhi 2012, 111:183-193.